This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.
The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.
EVRENZO (roxadustat) is the first HIF-PH inhibitor to have gained approval for the treatment of symptomatic anaemia associated with CKD. It mimics the body's physiological response to hypoxia3 by increasing production of erythropoietin and improving iron availability, thereby increasing haemoglobin levels and increasing red blood cell production with a reduced use of intravenous iron.1 EVRENZO is a tablet taken 3 times a week. We invite you to explore this website to discover the difference EVRENZO can make for your patients.
Why is anaemia of CKD difficult to treat?
What is the HIF pathway?
What is EVRENZO?
How does EVRENZO differ from other therapies?
How effective is EVRENZO in non-dialysis-dependent CKD (NDD-CKD)?
How does EVRENZO compare with ESA in non dialysis dependent (NDD) CKD?
How does EVRENZO compare with ESA in dialysis dependent (DD) CKD?
Is supplementary iron required with EVRENZO in non dialysis dependent (NDD) CKD?
Is supplementary iron required with EVRENZO in dialysis dependent (DD) CKD?
What is the cardiovascular safety profile of EVRENZO?
What is the tolerability profile of EVRENZO?
What are the haemoglobin monitoring requirements with EVRENZO?
How is EVRENZO administered?
What are the benefits of EVRENZO for patients?
Which patients may be suitable for EVRENZO?
Professor Jon Barratt on the disease burden
How does it feel to live with anaemia of CKD?
Professor Sunil Bhandari on the challenges of management
▼ Tähän lääkevalmisteeseen kohdistuu lisäseuranta. Tällä tavalla voidaan havaita nopeasti turvallisuutta koskevaa uutta tietoa. Terveydenhuollon ammattilaisia pyydetään ilmoittamaan epäillyistä lääkkeen haittavaikutuksista. Ks. kohdasta Haittavaikutukset, miten haittavaikutuksista ilmoitetaan
CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; HIF-PH, hypoxia-inducible factor prolyl-hydroxylase; NDD, non-dialysis-dependent.